Clomid vs Letrozole for PCOS: Why the Guideline Changed Its First Choice

What Is Clomid, and Is It Still Used for PCOS?

Clomid is the brand name for clomiphene citrate, a drug that has been the default PCOS fertility treatment for more than 40 years before its position changed in the last decade. Clomiphene works by blocking estrogen receptors at the hypothalamus, which the brain reads as a low-estrogen signal and responds to by increasing FSH output — the hormone that recruits and matures an ovarian follicle. It is still an approved, available, and reasonable option today; it is simply no longer the guideline’s automatic first pick, which is a different statement from being outdated.

That distinction between “no longer first choice” and “no longer used” matters, because plenty of PCOS forums and older resources still describe clomiphene as the standard, and a clinician offering letrozole instead can read as a surprise rather than the current standard of care. Both drugs are taken as a short oral course early in the cycle, both require monitoring to confirm a response, and both carry a real chance of not working on a first attempt — none of that changed between the two drugs. What changed was which one a clinician reaches for first when there is no specific reason to prefer the other.

What Is Letrozole, and Why Did It Overtake Clomid?

Letrozole took over as PCOS’s guideline-recommended first-line fertility drug in 2014, on the strength of a single trial, after years as a second-choice option despite a mechanism doctors had long suspected worked better. It is an aromatase inhibitor, originally developed for breast cancer, that works through a different mechanism entirely from clomiphene: it blocks the enzyme that converts androgens into estrogen, which drops circulating estrogen and triggers the same FSH rise clomiphene aims for, but through the opposite chemical route. That difference in mechanism has a practical consequence — letrozole does not carry clomiphene’s anti-estrogenic effect on the uterine lining and cervical mucus, which had long been suspected of working against clomiphene’s own ovulation-inducing effect on implantation. “Letrozole pcos” and “clomiphene pcos” are, in effect, two names for the same underlying question: which of these two mechanisms gets more people to a live birth per cycle.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same condition, same fertility drugs, same evidence — only the label changed. This article uses PCOS, since that is still the term most readers search.

The Head-to-Head Evidence That Changed the Guideline

Six earlier randomized trials, pooled across 841 patients, found no significant difference in pregnancy rate between letrozole and clomiphene, according to a 2011 meta-analysis — the evidence base going into the 2010s was genuinely inconclusive, not quietly in letrozole’s favor all along. What changed the picture was a single, much larger, better-designed trial.

The trial enrolled 750 women aged 18–40, diagnosed with PCOS by modified Rotterdam criteria (anovulation plus either hyperandrogenism or polycystic ovaries on ultrasound), each with at least one open fallopian tube, a normal uterine cavity, and a partner with a sperm concentration of at least 14 million per millilitre. Every couple intended regular, timed intercourse for the five-cycle treatment window. The live-birth gap — 27.5% versus 19.1%, a rate ratio of 1.44 — was large enough, in a trial this size, to be statistically decisive in a way six smaller trials combined had not managed to be.

Why the Guideline Changed Its First Choice

International PCOS guidelines shifted to recommend letrozole as the first-line ovulation-induction option following this trial, a position the 2023 international evidence-based guideline maintains. The reasoning is not just the live-birth number — it is that a single large, multicenter, double-blind trial funded by a national research institute (NICHD) carries more evidentiary weight than a pool of smaller, heterogeneous trials, even when the smaller pool is larger in raw patient count. Clomiphene has not been withdrawn or restricted; it remains a second-line or alternative option, particularly where letrozole is unavailable, not approved for the indication in a given country, or not tolerated.

The secondary findings mattered almost as much as the headline number. Letrozole’s higher cumulative ovulation rate — 61.7% of cycles versus 48.3% — showed the effect wasn’t confined to a handful of lucky outcomes; it held up across more than 2,700 pooled treatment cycles. And because neither the miscarriage rate nor the twin-pregnancy rate differed significantly between the two drugs in this trial, the guideline committee had a rare case where one option looked better on the primary outcome without a clear trade-off attached to it elsewhere — a combination that made the recommendation easier to write than most guideline updates get to be.

Why the Switch Took a Decade to Become Official

An unpublished 2005 conference presentation, never peer-reviewed, reported a higher malformation rate among babies conceived with letrozole and slowed the drug’s adoption for years despite its mechanism already looking promising. A retrospective study of 911 newborns from five Canadian fertility centres — 514 conceived with letrozole, 397 with clomiphene — found congenital malformations in 2.4% of the letrozole group versus 4.8% of the clomiphene group, and concluded the teratogenicity concern was unfounded. Letrozole is still used off-label for ovulation induction in some countries, including the United States, because it remains formally approved only for breast cancer — a regulatory quirk, not a reflection of the safety evidence, which is exactly why the international guideline explicitly weighing in mattered: it gave clinicians outside specialist fertility centres a clear reason to prescribe it as first-line despite the label.

Who This Will Not Work For

Combining letrozole with clomiphene more than doubled the odds of ovulation compared with letrozole alone — an odds ratio of 2.55 — across 592 women with anovulatory PCOS pooled from four randomized trials and two observational studies in a 2025 systematic review. Neither drug works for everyone alone, which is exactly why this combination gets used in practice for women who do not fully respond to a single agent. But the same review found no significant difference in pregnancy rate between the combination and letrozole alone, despite the better ovulation numbers. That nuance matters: more ovulation is not automatically more pregnancies, and it is exactly the kind of distinction worth raising directly with a fertility specialist rather than assuming a bigger response means a better outcome.

Body weight also changes how well either drug performs. Ovulation-induction response is generally weaker at a higher BMI, which is part of why insulin resistance is evaluated alongside any ovulation-induction plan rather than treated as a separate issue. Metformin is sometimes discussed in combination with these drugs for exactly that reason, though the guideline treats it as an adjunct to be discussed case by case rather than a routine addition — not a substitute for either drug, and not something to start without a clinician weighing the specific phenotype involved.

What to Discuss With Your Clinician Before Starting Either

A partner’s sperm concentration of at least 14 million per millilitre, a patent fallopian tube, and a normal uterine cavity were baseline requirements for every one of the 750 women in the pivotal 2014 trial above — a reminder that the same basic fertility work-up precedes ovulation-induction medication in ordinary practice, not just in a research study. Ovulation-induction medication is monitored, not self-directed: a clinician tracks response with ultrasound follicle tracking or timed hormone testing to confirm a cycle actually produced an egg and to watch for an excessive response before it becomes a multiple-pregnancy risk. None of this is a plan to follow independently; it is the set of questions a fertility appointment is built to answer for a specific case, including which of these two drugs — or whether a combination or an alternative entirely — actually fits.

For the wider picture of what realistic conception odds look like once treatment starts, the cumulative rates from named cohorts are covered in full here, and this comparison sits inside the site’s broader fertility coverage alongside it.

When to See a Fertility Specialist

Common questions